A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies	Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm	Active, not recruiting	Phase 1 / Phase 2	2026-04-23		NCT05428969

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Faron Pharmaceuticals Ltd	4

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope National Medical Center	Duarte	United States	68
Helsinki University Hospital	Helsinki	Finland	15
Kuopio University Hospital	Kuopio	Finland	15
Oulu University Hospital	Oulu	Finland	6
Royal Cornwall Hospitals NHS Trust	Truro	United Kingdom	4
Tampere University Hospital	Tampere	Finland	29
The Christie NHS Foundation Trust	Manchester	United Kingdom	40
UNC Lineberger Comprehensive Cancer Center	Chapel Hill	United States	243
University of Texas, MD Anderson Cancer Center	Houston	United States	12
Yale Cancer Center	New Haven	United States	42